PMID- 14654099
OWN - NLM
STAT- MEDLINE
DCOM- 20040405
LR  - 20190726
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 46
IP  - 1
DP  - 2004 Jan
TI  - Long-lasting behavioral sensitization to psychostimulants following 
      p-chloroamphetamine-induced neurotoxicity in mice.
PG  - 74-84
AB  - Amphetamine analogs such as p-chloroamphetamine (PCA) cause serotonergic and 
      dopaminergic neurotoxicity. The behavioral consequences and the responsiveness to 
      psychostimulants following the neurotoxic insult are unclear. The present study 
      was undertaken to investigate the outcome of neurotoxic and non-neurotoxic PCA 
      pre-treatments on the sensitivity of Swiss Webster mice to the psychomotor 
      stimulating effects of PCA, 3,4-methylenedioxymethamphetamine (MDMA) and cocaine. 
      PCA (15 mg/kg x 2; i.p.) caused 37-70% depletion of dopaminergic and serotonergic 
      markers in mouse brain. Saline and PCA (15 mg/kg x 2) mice were challenged on 
      days 5, 12, 40 and 74 with one of the following drugs: PCA (5 mg/kg), MDMA (10 
      mg/kg) and cocaine (20 mg/kg). The PCA pre-exposed mice showed marked locomotor 
      sensitization from days 5-74 to all three drugs tested. The time course of the 
      sensitized response coincided with the time course of the neurotoxic insult as 
      determined by reduced densities of striatal dopamine transporter and frontal 
      cortex serotonin transporter binding sites. A single injection of PCA (5 mg/kg) 
      caused neither neurotoxicity nor sensitization to the locomotor stimulating 
      effects of PCA, MDMA and cocaine. Repeated administration of a low non-neurotoxic 
      dose of PCA (5 mg/kg/day; 6 days) caused a transient locomotor sensitization to 
      PCA that dissipated after one month. Results of the present study suggest that 
      PCA-induced serotonergic and dopaminergic neurotoxicity coincides with 
      long-lasting locomotor sensitization to psychostimulants. These findings may be 
      relevant to the psychopathology of amphetamines-induced neurotoxicity.
FAU - Itzhak, Yossef
AU  - Itzhak Y
AD  - Department of Psychiatry and Behavioral Sciences (R-629), University of Miami 
      School of Medicine, Miami, FL 33136, USA.yitzhak@med.miami.edu
FAU - Achat-Mendes, Cindy N
AU  - Achat-Mendes CN
FAU - Ali, Syed F
AU  - Ali SF
FAU - Anderson, Karen L
AU  - Anderson KL
LA  - eng
GR  - DA12867/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Anesthetics, Local)
RN  - 0 (Carrier Proteins)
RN  - 0 (Dopamine Plasma Membrane Transport Proteins)
RN  - 0 (Hallucinogens)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Serotonin Agents)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
RN  - 0 (Slc6a4 protein, mouse)
RN  - 333DO1RDJY (Serotonin)
RN  - 64-12-0 (p-Chloroamphetamine)
RN  - I5Y540LHVR (Cocaine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Anesthetics, Local/pharmacology
MH  - Animals
MH  - Behavior, Animal/*drug effects
MH  - Binding Sites/drug effects
MH  - Brain Chemistry/drug effects
MH  - Carrier Proteins/metabolism
MH  - Chromatography, High Pressure Liquid/methods
MH  - Cocaine/*pharmacology
MH  - Dopamine/metabolism
MH  - Dopamine Plasma Membrane Transport Proteins
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Hallucinogens/*pharmacology
MH  - Male
MH  - Membrane Glycoproteins/metabolism
MH  - Membrane Transport Proteins/metabolism
MH  - Mice
MH  - Motor Activity/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - *Nerve Tissue Proteins
MH  - Neurotoxicity Syndromes/etiology
MH  - Serotonin/metabolism
MH  - Serotonin Agents/*toxicity
MH  - Serotonin Plasma Membrane Transport Proteins
MH  - Time Factors
MH  - p-Chloroamphetamine/*toxicity
EDAT- 2003/12/05 05:00
MHDA- 2004/04/06 05:00
CRDT- 2003/12/05 05:00
PHST- 2003/12/05 05:00 [pubmed]
PHST- 2004/04/06 05:00 [medline]
PHST- 2003/12/05 05:00 [entrez]
AID - S0028390803003162 [pii]
AID - 10.1016/s0028-3908(03)00316-2 [doi]
PST - ppublish
SO  - Neuropharmacology. 2004 Jan;46(1):74-84. doi: 10.1016/s0028-3908(03)00316-2.